Benutzer: Gast  Login
Dokumenttyp:
journal article 
Autor(en):
Koerber, Stefan Alexander; Slynko, Alla; Haefner, Matthias F; Krug, David; Schoneweg, Clara; Kessel, Kerstin; Kopp-Schneider, Annette; Herfarth, Klaus; Debus, Juergen; Sterzing, Florian 
Titel:
Efficacy and toxicity of chemoradiation in patients with anal cancer--a retrospective analysis. 
Abstract:
Concurrent chemotherapy and radiation therapy is the preferred standard of care for patients with anal cancer. Several studies have suggested a benefit of intensity-modulated radiation therapy (IMRT) compared with 3D-conformal radiation (3D-CRT) regarding acute toxicity. This study evaluates outcome and toxicity of patients undergoing IMRT/Tomotherapy or 3D-CRT at our institution.A cohort of 105 anal cancer patients was treated with chemoradiation or radiation alone (16.2%) between January 2000 and December 2011. 37 patients received 3D-CRT while 68 patients were treated with IMRT. Follow-up exams were performed every 3 to 6 months for a minimum of 3 years and then annually.Median follow-up was 41.4 months (2.8 - 158.4). Overall survival (OS), Progression-free survival (PFS) and local control (LC) at 3 years was 70.3%, 66.5%, 78.3% in the 3D-CRT group and 82.9%, 66.5%, 75.3% in the IMRT group without statistically significant difference. 3-year Colostomy-free survival (CFS) was 85.7% in the IMRT/Tomotherapy group and 91.8% in the 3D-CRT group (p = 0.48). No grade 4 toxicity was found in both groups. Severe (G2/3) acute skin toxicity (94.6% vs. 63.2%; p< 0.001) and acute gastrointestinal toxicity rate (67.6% vs. 47.1%; p = 0.03) was significantly higher with 3D-CRT compared to IMRT/Tomotherapy.The use of IMRT can reduce acute severe side effects of the skin and gastrointestinal tract but did not demonstrate improved results regarding OS, PFS, LC and CFS. 
Zeitschriftentitel:
Radiat Oncol 
Jahr:
2014 
Band / Volume:
Seitenangaben Beitrag:
113 
Sprache:
eng 
TUM Einrichtung:
Klinik und Poliklinik für RadioOnkologie und Strahlentherapie